Control Bionics (ASX:CBL): September Cash Position and Neurotechnology Rollout

Aditi Sarkar

29 October 2026 05:11 PM AEDT

Control Bionics (ASX:CBL): September Cash Position and Neurotechnology Rollout

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Quarter-end cash increased to $5.79m after a $9.75m capital raising.
Customer receipts were $999k during the September quarter.
NeuroStrip gained US and UK registrations and later CE marking.
NextLevel OMNI made initial shipments and recorded revenue in September.
The company reported 2.1 quarters of funding at the quarter-end outflow rate.

Control Bionics Limited (ASX:CBL) develops assistive communication and sensor-based neurotechnology products, including NeuroNode and NeuroStrip. Its September 2026 quarterly report recorded cash at bank of $5.79m following completion of a $9.75m capital raising, compared with $2.08m at 30 June. The update also covered new product shipments, regulatory registrations and early NeuroStrip customer trials, alongside continuing operating cash expenditure.

Receipts and cash movements

Control Bionics (ASX:CBL) recorded $999k in customer receipts for the September quarter, described as broadly unchanged from the preceding quarter. The company reported unaudited monthly revenue growth throughout the period, although it did not disclose a quarterly revenue figure. Operating cash outflow was $2.75m, including approximately $0.8m in one-off or non-recurring expenditure, and investing outflow was $156k. Net financing inflow reached $6.64m. Management said its September-weighted trading performance could influence December-quarter collections, but this remains subject to payment timing rather than a reported cash result.

Capital raising and funding runway

The $9.75m capital raising was priced at 7.5 cents per share and completed through two tranches and a share purchase plan. Control Bionics (ASX:CBL) said the second tranche settled on 11 August 2026. It repaid a $400k research and development loan that day, while $21,334 remained on an insurance finance facility at the quarter end, repayable by 30 October. A further $440,531 R&D refund arrived in early October, after quarter end. Appendix 4C showed an estimated 2.1 quarters of funding at reported spending levels. Management separately stated that its operating plan anticipated funding through FY27 without another raising before cash-flow breakeven; that expectation is not a guarantee.

NextLevel OMNI and NeuroNode distribution

NextLevel OMNI, an iOS-based speech-generating device, received a Medicare PDAC code on 27 August 2026. First units were shipped and revenue recognised in September. Control Bionics (ASX:CBL) also described NeuroNode distribution in the United States and Germany. A German arrangement launched on 23 September is non-exclusive, lasts 12 months and carries no minimum purchase commitment. NeuroNode was added to Germany's Medical Aids Directory in March 2026, allowing reimbursement through statutory health insurance. Distribution access and reimbursement eligibility are separate from an assured volume of customer orders.

NeuroStrip registrations and early use

NeuroStrip was registered and listed as a medical device with the US FDA in August 2026 and registered with the UK MHRA during the same month. Following quarter end, Control Bionics (ASX:CBL) obtained CE marking as a Class I device, while an Australian TGA application remained pending. The company reported engagement with approximately 80 organisations, up from around 20 in July, with about 30 conducting live trials and four paying customers. Customer sessions totalled 282, an increase of 103 per cent on the June quarter. These adoption measures demonstrate trial activity, but do not establish a broad paying customer base.

Operational expectations and execution risk

For FY27, Control Bionics (ASX:CBL) reaffirmed an expectation of 50 per cent revenue growth compared with FY26, weighted to the second half. It also anticipated progress in converting NeuroStrip trials, an increasing wholesale contribution and monthly profitability in its Assistive Communication business during the first half. The planned US launch of a NeuroStrip prehabilitation programme and general release of brain-computer interface integration are further milestones. The company identified prolonged Australian disability-funding approvals, partner training time and uncertain conversion from trials to paid contracts as risks. These milestones and financial expectations remain forward-looking company statements.

Key Insights

Control Bionics (ASX:CBL) reported a higher cash balance and several regulatory and distribution developments in 2026. Its quarterly figures also show continued operating outflows and a limited number of paying NeuroStrip customers. Product access, customer adoption and management's FY27 expectations are distinct measures of progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.